Bristol Myers on track for 3rd new drug launch of 2022 with latest deucravacitinib data

Bristol Myers Squibb just released new two-year deucravacitinib data showing lasting efficacy for patients with moderate to severe plaque psoriasis. It means the drug could be going head-to-head with Amgen's Otezla as soon as September.